Biotech RadarJobs updated

COMPANY

Skyhawk Therapeutics

HQ: Waltham, MA (US office) source · skyhawktx.com ↗ · New England

Clinical Phase 3

2 open jobs · last seen Oct 23, 2026 · 4 sources

We make orally-administered small molecule pills, taken daily, that bind to RNA and modify downstream protein production. From company website Source · Oct 12, 2026

Keywords: small molecule Huntington Disease Huntington's Disease SKY-0515

Location: Waltham, MA (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Open jobs3Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Clinical Trial AssociateWaltham, MAOct 7, 2026Oct 7, 2026
Clinical Trial ManagerWaltham, MAAug 27, 2026Oct 9, 2026

See all 2 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
  2. Trial start Phase 2/Phase 3: An Extension of SKY-0515 in Participants With Huntington's Disease source ↗
  3. Trial start Phase 2/Phase 3: Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease source ↗
  4. Trial start Phase 2/Phase 3: Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 2

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Clinical Trial AssociateWaltham, MAOct 7, 2026Oct 7, 2026Mid
Clinical Trial ManagerWaltham, MAAug 27, 2026Oct 9, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT07378644Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseasePhase 2/Phase 3RecruitingJan 6, 20262028-12 (estimated)
NCT07537075An Extension of SKY-0515 in Participants With Huntington's DiseasePhase 2/Phase 3Enrolling by invitationApr 10, 20262029-12 (estimated)
NCT06873334Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's DiseasePhase 2/Phase 3Active, not recruitingMay 27, 20252027-05 (estimated)

Connect

See your connections at Skyhawk Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback